Target intelligence / Profile preview

HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1*03:01) (HLA-DRB1*03:01)

Target
HLA-DRB1*03:01
Molecular classification
MHC class II, Receptor, Antigen-presenting molecule
01

Overview

HLA-DRB1*03:01 is a specific allele of the Human Leukocyte Antigen (HLA) class II beta chain, which forms a heterodimer with the alpha chain to create the HLA-DR molecule (UniProt: P01912). The peptide-binding groove of this molecule plays a critical role in the adaptive immune system by presenting exogenous peptides to CD4+ T-helper cells. This specific allele is highly associated with several autoimmune conditions, including Type 1 Diabetes, Graves' disease, and Systemic Lupus Erythematosus, where it may inappropriately present self-antigens, leading to a loss of immune tolerance (PMID: 11889178, PMID: 15099134). The groove features specific pockets (P1, P4, P6, P7, and P9) that dictate the binding affinity of peptide side chains, which is a key determinant of the immune repertoire. Therapeutic strategies targeting the HLA-DRB1*03:01 peptide-binding groove often involve the use of peptide mimetics or small molecules designed to block the presentation of pathogenic self-peptides or to induce regulatory T-cell responses. Understanding the structural motifs of this groove is essential for developing precision immunotherapies that can modulate the immune response without causing broad immunosuppression (PMID: 15604398).

Other names
HLA-DR3DRB1*0301MHC class II antigen DRB1*03:01Human leukocyte antigen DRB1*03:01DRB1*03:01 peptide-binding groove
02

Mechanism of action

Competitive inhibition of peptide binding within the MHC groove to prevent pathogenic T-cell activation or to induce immune tolerance through the presentation of altered peptide ligands.

03

Biological functions

Antigen presentationImmune responseT-cell activationSelf-tolerance
04

Disease associations

Type 1 DiabetesGraves' diseaseSystemic Lupus ErythematosusMyasthenia GravisSjogren's syndromeAutoimmune disease
05

Safety considerations

Risk of systemic immunosuppressionPotential for inducing hypersensitivity or anaphylaxisComplexity of HLA polymorphism leading to off-target effectsRisk of exacerbating autoimmune responses
06

Interacting drugs

Glatiramer acetate

3 more in the full profile.

07

Biomarkers

HLA-DRB1*03:01 allele presenceAnti-GAD65 antibodiesAnti-islet cell antibodiesAnti-TSH receptor antibodies

Beyond the preview

Go deeper on HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1*03:01) (HLA-DRB1*03:01).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1*03:01) (HLA-DRB1*03:01).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call